Venturing Towards Innovation

Transcription

1 Venturing Towards Innovation Jeff Dykan Managing Partner Tokyo and Taipei March 2014

2 Overview of Vitalife $US 230 million under management in 2 Venture Capital Funds Focus on Israeli based companies developing breakthrough medical technologies serving large global markets Unique deal flow in defense related technologies General partners in Israel and US with rich experience in venture capital, medical technology and commercialization > Lead portfolio business development efforts High profile exits and promising portfolio companies Network with CEO s at all global medtech companies Recent portfolio strategic investments and agreements in Japan and China Investors include NYC Pension Funds, New York Common Retirement Fund, MassPRIM, major Israeli pension funds, insurance companies and medical technology corporate investors Offices with full teams in Tel Aviv and Philadelphia 2

3 Does Israel have Relative Strength in MedTech? Global healthcare crisis - Aging population - Rising healthcare costs Solutions - Leading edge technologies - Biomaterials - Home based monitoring Results in better care at lower cost! Israel has a strong advantage Highest number of medtech patents filed in the world per capita World class teaching hospitals and universities Global reputation in development of leading edge technology Unique Vitalife dealflow source > adaptation of defense related technologies Top global medtech companies continuously scout Israeli startups 3

4 Medical Robotics and Automation Developed ReWalk exoskeleton, allowing paraplegics to stand, walk and climb stairs > HUGE market potential Systems in over 40 leading rehabilitations centers in Europe and US, demonstrated to President Obama Strategic investment and partnership with Yaskawa Electric Corporation Commercializing an advanced laparoscope positioning and imaging system Cost effective, small footprint system utilizes advanced proprietary video analytics Provides surgeon full control and a highly stable image throughout the procedure. Developing world s first fully automated microbiology IVD platform Reagent free, real-time system will revolutionize In Vitro Diagnostics 4

5 Breakthrough Technologies Developing worlds first artificial pancreas, complete solution for Type 1 Diabetics 2013: First ever transplant of islets without immunosuppressive drugs Developed CardioFit System for the treatment of heart failure Strategic agreement with Medtronic to fund pivotal trial with option to acquire World leader in corneal cross linking refractive surgery Strategic partner > Shinigawa Lasik Center Japan Management team led $1 billion exit at prior company 5

6 Defense technologies adaptations Spun out of Elbit Systems by Vitalife, board led by Vitalife acquired by St Jude medical for $300M Medical GPS in that it uses a low-powered electromagnetic field to locate device-based sensors in 3D space Allows use of pre-recorded X-ray image, which allows reduced duration of live X-ray during a procedure Spun out of SCD by Vitalife, board led by SCP Vitalife DIR is a leading developer and manufacturer of pharmaceutical quality assurance applications Global leader in use of Dynamic Thermography for pharmaceutical applications Used in Process Analytical Technology (PAT) and nondestructive drug authentication Adapting See through Walls technology for heart failure monitoring > HUGE global market opportunity Goal is for device is to become the Glucometer for heart failure patients Strategic investment by Boston Scientific and Chinese investor LaborPro breakthrough in non-invasive monitoring of labor progress TrigGuide breakthrough for guided ultrasound procedures for biopsy and other interventional tools Strategic investment by LaborPro partner in China 6

7 Novel Materials Developed unique biomaterial for aesthetics and dental applications Turnaround led by Vitalife Acquired by J&J for $159M 18 months following investment GelrinC, a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to knee Cartilage regeneration one of the holy grails of orthopedics > HUGE market potential Strategic investment from Royal DSM Develops advanced low profile stent-grafts systems for the treatment of aneurysms Allows for a shorter, simpler and less invasive procedure Recent investment by Sequoia Capital first medical technology investment in Israel 7

8 THANK YOU Wayne, PA Tel-Aviv, IL